Skip to Main Content

Good morning, everyone, and nice to see you again. We have returned after a pleasant week away and, not surprisingly, are playing a bit of catchup as we ease in to the customary routines. This includes, of course, a few cups of stimulation, beginning with cinnamon vanilla nut. We hope your own summer is proceeding nicely, meanwhile, as the vacation season draws to a close. To what extent this suggests the next few days will be subdued, however, remains to be seen. Speculation aside, here are some tidbits as you ponder the possibilities. Hope your day goes well and do stay in touch …

A campaign by Bayer (BAYRY) and Johnson & Johnson (JNJ) to widen the market for the Xarelto bloodthinner hit a snag when a study for a potential new patient subgroup failed to show a statistically reliant benefit, Reuters writes. The blockbuster drug could not be shown to reduce the rate of dangerous blood clots in a certain group of high-risk patients after discharge from hospital. Participants in the so-called Mariner study had previously been admitted to a hospital for a range of conditions that are associated with a higher risk of venous thromboembolism.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!